Previously, we showed that peripheral neuropathy of the bone marrow was associated with loss of circadian rhythmicity of stem/progenitor cell release into the circulation. Bone marrow neuropathy results in dramatic changes in hematopoiesis that lead to microvascular complications, inflammation and reduced endothelial repair. This series of events represents early pathogenesis before development of diabetic retinopathy. In the present study, we characterized early alterations within the bone marrow of streptozotocin (STZ)-induced diabetic rats following treatments that prevent experimental, peripheral neuropathy. We asked whether bone marrow neuropathy and the associated bone marrow pathology were reversed with treatments that prevent peripheral neuropathy. Three strategies were tested: inhibition of neutral endopeptidase, inhibition of aldose reductase plus lipoic acid supplementation and insulin therapy with antioxidants. All strategies prevented STZ-diabetes induced loss of nerve conduction velocity and corrected the STZ-diabetes associated increases of immunoreactivity for neuropeptide Y, tyrosine hydroxylase and somatostatin. The treatments also reduced levels of IL-1β, granulocyte colony-stimulating factor and MMP-2 in STZ-induced diabetic bone marrow supernatant and decreased the expression of NOX-2, NOS-2 and NF-κB1 mRNA in bone marrow progenitor cells. These therapies represent novel approaches to attenuate the diabetic phenotype within the bone marrow and may constitute an important therapeutic strategy for diabetic microvascular complications.
Pharmacology, Toxicology and Pharmaceutical Science
4
7%
Neuroscience
3
5%
Other
4
7%
Unknown
23
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 April 2015.
All research outputs
#16,286,633
of 25,918,104 outputs
Outputs from Diabetes
#7,813
of 9,918 outputs
Outputs of similar age
#135,553
of 252,741 outputs
Outputs of similar age from Diabetes
#127
of 179 outputs
Altmetric has tracked 25,918,104 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 9,918 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,741 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 179 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
